(OGN) Organon - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US68622V1061
Stock: Womens Health, Biosimilars, Pharmaceuticals
Total Rating 22
Risk 73
Buy Signal -1.68
| Risk 5d forecast | |
|---|---|
| Volatility | 44.5% |
| Relative Tail Risk | -11.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.14 |
| Alpha | -77.33 |
| Character TTM | |
|---|---|
| Beta | 0.859 |
| Beta Downside | 1.623 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.34% |
| CAGR/Max DD | -0.44 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: OGN Organon March 05, 2026
Organon & Co. (OGN) develops and sells womens health solutions, prescription therapies, and medical devices globally. The company operates in the pharmaceutical sector, which is characterized by extensive research and development cycles and regulatory approval processes.
Its womens health portfolio includes contraception (e.g., Nexplanon, NuvaRing) and fertility treatments (e.g., Follistim AQ, Elonva). OGN also markets a biosimilars portfolio, encompassing immunology and oncology products, and a range of established brands for conditions such as high cholesterol, hypertension, respiratory issues, dermatology, bone health, and non-opioid pain management.
The companys business model involves serving a diverse client base, including drug wholesalers, retailers, hospitals, and government agencies. To gain further insights into OGNs financial performance and market position, consider exploring its detailed profile on ValueRay.
Headlines to watch out for
- Womens health product sales drive revenue growth
- Biosimilars portfolio expansion impacts market share
- Generic competition erodes established drug revenue
- Regulatory approvals for new therapies boost stock
- Global healthcare spending trends affect demand
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 187.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.46 > 1.0 |
| NWC/Revenue: 31.56% < 20% (prev 25.46%; Δ 6.11% < -1%) |
| CFO/TA 0.05 > 3% & CFO 700.0m > Net Income 187.0m |
| Net Debt (8.23b) to EBITDA (1.30b): 6.33 < 3 |
| Current Ratio: 1.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (260.2m) vs 12m ago 0.11% < -2% |
| Gross Margin: 53.59% > 18% (prev 0.58%; Δ 5.30k% > 0.5%) |
| Asset Turnover: 47.87% > 50% (prev 48.87%; Δ -1.00% > 0%) |
| Interest Coverage Ratio: 1.84 > 6 (EBITDA TTM 1.30b / Interest Expense TTM 505.0m) |
Altman Z'' 1.81
| A: 0.15 (Total Current Assets 4.35b - Total Current Liabilities 2.39b) / Total Assets 12.87b |
| B: 0.09 (Retained Earnings 1.11b / Total Assets 12.87b) |
| C: 0.07 (EBIT TTM 929.0m / Avg Total Assets 12.98b) |
| D: 0.05 (Book Value of Equity 585.0m / Total Liabilities 12.12b) |
| Altman-Z'' Score: 1.81 = BBB |
Beneish M -3.03
| DSRI: 0.99 (Receivables 1.43b/1.49b, Revenue 6.22b/6.40b) |
| GMI: 1.08 (GM 53.59% / 58.02%) |
| AQI: 0.99 (AQ_t 0.56 / AQ_t-1 0.57) |
| SGI: 0.97 (Revenue 6.22b / 6.40b) |
| TATA: -0.04 (NI 187.0m - CFO 700.0m) / TA 12.87b) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of OGN shares?
As of March 17, 2026, the stock is trading at USD 6.34 with a total of 3,536,534 shares traded.
Over the past week, the price has changed by -2.91%, over one month by -12.70%, over three months by -8.81% and over the past year by -59.02%.
Over the past week, the price has changed by -2.91%, over one month by -12.70%, over three months by -8.81% and over the past year by -59.02%.
Is OGN a buy, sell or hold?
Organon has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold OGN.
- StrongBuy: 0
- Buy: 2
- Hold: 3
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the OGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9 | 42% |
| Analysts Target Price | 9 | 42% |
OGN Fundamental Data Overview March 13, 2026
P/E Trailing = 8.8889
P/E Forward = 5.0302
P/S = 0.268
P/B = 2.2155
Revenue TTM = 6.22b USD
EBIT TTM = 929.0m USD
EBITDA TTM = 1.30b USD
Long Term Debt = 8.63b USD (from longTermDebt, last quarter)
Short Term Debt = 56.0m USD (from shortTermDebt, last quarter)
Debt = 8.80b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.23b USD (from netDebt column, last quarter)
Enterprise Value = 9.89b USD (1.67b + Debt 8.80b - CCE 574.0m)
Interest Coverage Ratio = 1.84 (Ebit TTM 929.0m / Interest Expense TTM 505.0m)
EV/FCF = 24.49x (Enterprise Value 9.89b / FCF TTM 404.0m)
FCF Yield = 4.08% (FCF TTM 404.0m / Enterprise Value 9.89b)
FCF Margin = 6.50% (FCF TTM 404.0m / Revenue TTM 6.22b)
Net Margin = 3.01% (Net Income TTM 187.0m / Revenue TTM 6.22b)
Gross Margin = 53.59% ((Revenue TTM 6.22b - Cost of Revenue TTM 2.88b) / Revenue TTM)
Gross Margin QoQ = 50.36% (prev 53.50%)
Tobins Q-Ratio = 0.77 (Enterprise Value 9.89b / Total Assets 12.87b)
Interest Expense / Debt = 1.38% (Interest Expense 121.0m / Debt 8.80b)
Taxrate = 21.0% (US default 21%)
NOPAT = 733.9m (EBIT 929.0m * (1 - 21.00%))
Current Ratio = 1.82 (Total Current Assets 4.35b / Total Current Liabilities 2.39b)
Debt / Equity = 11.70 (Debt 8.80b / totalStockholderEquity, last quarter 752.0m)
Debt / EBITDA = 6.33 (Net Debt 8.23b / EBITDA 1.30b)
Debt / FCF = 20.36 (Net Debt 8.23b / FCF TTM 404.0m)
Total Stockholder Equity = 733.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.44% (Net Income 187.0m / Total Assets 12.87b)
RoE = 25.50% (Net Income TTM 187.0m / Total Stockholder Equity 733.2m)
RoCE = 9.92% (EBIT 929.0m / Capital Employed (Equity 733.2m + L.T.Debt 8.63b))
RoIC = 7.67% (NOPAT 733.9m / Invested Capital 9.56b)
WACC = 2.36% (E(1.67b)/V(10.47b) * Re(9.08%) + D(8.80b)/V(10.47b) * Rd(1.38%) * (1-Tc(0.21)))
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.70%
[DCF] Terminal Value 86.76% ; FCFF base≈483.6m ; Y1≈505.1m ; Y5≈583.5m
[DCF] Fair Price = 34.94 (EV 17.32b - Net Debt 8.23b = Equity 9.09b / Shares 260.3m; r=5.90% [WACC]; 5y FCF grow 4.76% → 2.90% )
EPS Correlation: -61.28 | EPS CAGR: -22.64% | SUE: -1.56 | # QB: 0
Revenue Correlation: 11.78 | Revenue CAGR: -1.04% | SUE: -0.34 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.94 | Chg7d=+0.049 | Chg30d=-0.086 | Revisions Net=-2 | Analysts=6
EPS current Year (2026-12-31): EPS=3.47 | Chg7d=+0.017 | Chg30d=-0.404 | Revisions Net=-6 | Growth EPS=-5.3% | Growth Revenue=-0.7%
EPS next Year (2027-12-31): EPS=3.73 | Chg7d=+0.021 | Chg30d=-0.188 | Revisions Net=-3 | Growth EPS=+7.5% | Growth Revenue=+0.8%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -2.2% (Discount Rate 9.1% - Earnings Yield 11.2%)
[Growth] Growth Spread = +0.6% (Analyst -1.6% - Implied -2.2%)
P/E Forward = 5.0302
P/S = 0.268
P/B = 2.2155
Revenue TTM = 6.22b USD
EBIT TTM = 929.0m USD
EBITDA TTM = 1.30b USD
Long Term Debt = 8.63b USD (from longTermDebt, last quarter)
Short Term Debt = 56.0m USD (from shortTermDebt, last quarter)
Debt = 8.80b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.23b USD (from netDebt column, last quarter)
Enterprise Value = 9.89b USD (1.67b + Debt 8.80b - CCE 574.0m)
Interest Coverage Ratio = 1.84 (Ebit TTM 929.0m / Interest Expense TTM 505.0m)
EV/FCF = 24.49x (Enterprise Value 9.89b / FCF TTM 404.0m)
FCF Yield = 4.08% (FCF TTM 404.0m / Enterprise Value 9.89b)
FCF Margin = 6.50% (FCF TTM 404.0m / Revenue TTM 6.22b)
Net Margin = 3.01% (Net Income TTM 187.0m / Revenue TTM 6.22b)
Gross Margin = 53.59% ((Revenue TTM 6.22b - Cost of Revenue TTM 2.88b) / Revenue TTM)
Gross Margin QoQ = 50.36% (prev 53.50%)
Tobins Q-Ratio = 0.77 (Enterprise Value 9.89b / Total Assets 12.87b)
Interest Expense / Debt = 1.38% (Interest Expense 121.0m / Debt 8.80b)
Taxrate = 21.0% (US default 21%)
NOPAT = 733.9m (EBIT 929.0m * (1 - 21.00%))
Current Ratio = 1.82 (Total Current Assets 4.35b / Total Current Liabilities 2.39b)
Debt / Equity = 11.70 (Debt 8.80b / totalStockholderEquity, last quarter 752.0m)
Debt / EBITDA = 6.33 (Net Debt 8.23b / EBITDA 1.30b)
Debt / FCF = 20.36 (Net Debt 8.23b / FCF TTM 404.0m)
Total Stockholder Equity = 733.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.44% (Net Income 187.0m / Total Assets 12.87b)
RoE = 25.50% (Net Income TTM 187.0m / Total Stockholder Equity 733.2m)
RoCE = 9.92% (EBIT 929.0m / Capital Employed (Equity 733.2m + L.T.Debt 8.63b))
RoIC = 7.67% (NOPAT 733.9m / Invested Capital 9.56b)
WACC = 2.36% (E(1.67b)/V(10.47b) * Re(9.08%) + D(8.80b)/V(10.47b) * Rd(1.38%) * (1-Tc(0.21)))
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.70%
[DCF] Terminal Value 86.76% ; FCFF base≈483.6m ; Y1≈505.1m ; Y5≈583.5m
[DCF] Fair Price = 34.94 (EV 17.32b - Net Debt 8.23b = Equity 9.09b / Shares 260.3m; r=5.90% [WACC]; 5y FCF grow 4.76% → 2.90% )
EPS Correlation: -61.28 | EPS CAGR: -22.64% | SUE: -1.56 | # QB: 0
Revenue Correlation: 11.78 | Revenue CAGR: -1.04% | SUE: -0.34 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.94 | Chg7d=+0.049 | Chg30d=-0.086 | Revisions Net=-2 | Analysts=6
EPS current Year (2026-12-31): EPS=3.47 | Chg7d=+0.017 | Chg30d=-0.404 | Revisions Net=-6 | Growth EPS=-5.3% | Growth Revenue=-0.7%
EPS next Year (2027-12-31): EPS=3.73 | Chg7d=+0.021 | Chg30d=-0.188 | Revisions Net=-3 | Growth EPS=+7.5% | Growth Revenue=+0.8%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -2.2% (Discount Rate 9.1% - Earnings Yield 11.2%)
[Growth] Growth Spread = +0.6% (Analyst -1.6% - Implied -2.2%)